Combined intravitreal anti-VEGF and photodynamic therapy versus photodynamic monotherapy for polypoidal choroidal vasculopathy: A systematic review and meta-analysis of comparative studies

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Wang, Wei ^a   He, Miao ^a   Zhang, Xiulan ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR; VASCULOTROPIN A;

ADD ON THERAPY; CLINICAL EFFECTIVENESS; DATA ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTERMETHOD COMPARISON; INTERVENTION STUDY; MAJOR CLINICAL STUDY; META ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT SAFETY; PHOTODYNAMIC THERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RETINA DETACHMENT; RETINA HEMORRHAGE; RETINAL THICKNESS; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; VISUAL ACUITY; ADVERSE EFFECTS; AGED; ANTAGONISTS AND INHIBITORS; CHOROID DISEASES; COMPARATIVE STUDY; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PERIPHERAL VASCULAR DISEASES; PHOTOCHEMOTHERAPY; PUBLISHING; TREATMENT OUTCOME;

AGED; CHOROID DISEASES; COMBINED MODALITY THERAPY; HUMANS; INTRAVITREAL INJECTIONS; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PHOTOCHEMOTHERAPY; PUBLICATION BIAS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84908551436     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110667     Document Type: Review

References (36)

1. Sakurada Y, Yoneyama S, Imasawa M, Iijima H (2013) Systemic risk factors associated with polypoidal choroidal vasculopathy and neovascular age-related macular degeneration. Retina 33: 841-845.
2. Imamura Y, Engelbert M, Iida T, Freund KB, Yannuzzi LA (2010) Polypoidal choroidal vasculopathy: a review. Surv Ophthalmol 55: 501-515.
3. Gomi F, Tano Y (2008) Polypoidal choroidal vasculopathy and treatments. Curr Opin Ophthalmol 19: 208-212.
4. Nowak-Sliwinska P, van den Bergh H, Sickenberg M, Koh AH (2013) Photodynamic Therapy for Polypoidal Choroidal Vasculopathy. Prog Retin Eye Res.
5. Spaide RF, Donsoff I, Lam DL, Yannuzzi LA, Jampol LM, et al. (2012) Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. 2002. Retina 32 Suppl 1: 529-535.
6. Tomita K, Tsujikawa A, Yamashiro K, Ooto S, Tamura H, et al. (2012) Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab. Am J Ophthalmol 153: 68-80.
7. Oishi A, Kojima H, Mandai M, Honda S, Matsuoka T, et al. (2013) Comparison of the Effect of Ranibizumab and Verteporfin for Polypoidal Choroidal Vasculopathy: 12-Month LAPTOP Study Results. Am J Ophthalmol 156: 644-651.
8. Rouvas AA, Papakostas TD, Ntouraki A, Douvali M, Vergados I, et al. (2011) Photodynamic therapy, ranibizumab, and ranibizumab with photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Retina 31: 464-474.
9. Inoue M, Arakawa A, Yamane S, Kadonosono K (2013) Long-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy. Eye (Lond) 27: 1013-1021.
10. Lee MY, Lee WK, Baek J, Kwon OW, Lee JH (2013) Photodynamic Therapy Versus Combination Therapy in Polypoidal Choroidal Vasculopathy: Changes of Aqueous Vascular Endothelial Growth Factor. Am J Ophthalmol. 156: 343-8
11. Saito M, Iida T, Kano M, Itagaki K (2013) Two-year results of combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 251: 2099-110
12. Sakurada Y, Iijima H (2013) Two-Year Results of Photodynamic Therapy With or Without Intravitreal Ranibizumab for Polypoidal Choroidal Vasculopathy. J Ocul Pharmacol Ther. 29: 832-6
13. Kang HM, Koh HJ (2014) Two-Year Outcome after Combination Therapy for Polypoidal Choroidal Vasculopathy: Comparison with Photodynamic Monotherapy and Anti-Vascular Endothelial Growth Factor Monotherapy. Ophthalmologica. 231: 86-93.
14. Lee YA, Yang CH, Yang CM, Ho TC, Lin CP, et al. (2012) Photodynamic therapy with or without intravitreal bevacizumab for polypoidal choroidal vasculopathy: two years of follow-up. Am J Ophthalmol 154: 872-880.
15. Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, et al. (2012) EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 32: 1453-1464.
16. Kim SJ, Yu HG (2011) Efficacy of combined photodynamic therapy and intravitreal bevacizumab injection versus photodynamic therapy alone in polypoidal choroidal vasculopathy. Retina 31: 1827-1834.
17. Lai TY, Lee GK, Luk FO, Lam DS (2011) Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy. Retina 31: 1581-1588.
18. Maruko I, Iida T, Sugano Y, Saito M, Sekiryu T (2011) Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 151: 594-603.
19. Gomi F, Sawa M, Wakabayashi T, Sasamoto Y, Suzuki M, et al. (2010) Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 150: 48-54.
20. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62: 1006-1012.
21. Higgins JP, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March, 2011]: The Cochrane Collaboration. http://handbook.cochrane.org/
22. Wells G, Shea B, O'Connell D, Peterson J, Welch V, et al. The Newcastle- Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp
23. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
24. Koh AH, Chen LJ, Chen SJ, Chen Y, Giridhar A, et al. (2013) Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. Retina 33: 686-716.
25. Englander M, Kaiser PK (2013) Combination therapy for the treatment of neovascular age-related macular degeneration. Curr Opin Ophthalmol 24: 233-238.
26. Sato T, Kishi S, Matsumoto H, Mukai R (2013) Comparisons of outcomes with different intervals between adjunctive ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 156: 95-105.
27. Gemmy CC, Yeo I, Li X, Mathur R, Lee SY, et al. (2013) Argon laser with and without anti-vascular endothelial growth factor therapy for extrafoveal polypoidal choroidal vasculopathy. Am J Ophthalmol 155: 295-304.
28. Song MH, Ryu HW, Roh YJ (2011) One-year results of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy. Ophthalmologica 226: 119-126.
29. Lai TY, Chan WM, Liu DT, Luk FO, Lam DS (2008) Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Br J Ophthalmol 92: 661-666.
30. Ruamviboonsuk P, Tadarati M, Vanichvaranont S, Hanutsaha P, Pokawattana N (2010) Photodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy: results of a 1-year preliminary study. Br J Ophthalmol 94: 1045-1051.
31. Saito M, Iida T, Kano M (2012) Combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy. Retina 32: 1272-1279.
32. de Crecchio G, Chan RV, Manzi G, Romano MR (2011) Polypoidal choroidal vasculopathy: recent advances in therapy. Curr Drug Targets 12: 206-211.
33. Krebs I, Schmetterer L, Boltz A, Told R, Vecsei-Marlovits V, et al. (2013) A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol 97: 266-271.
34. Kodjikian L, Souied EH, Mimoun G, Mauget-Faysse M, Behar-Cohen F, et al. (2013) Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology. 120: 2300-9
35. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, et al. (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 382: 1258-1267.
36. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al. (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119: 1388-1398.